ConductScience.org, home

Paper32192585

Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.

Lan Z and 22 others. Lancet Respir Med, 2020. Cited by 203 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Download JSON
Cite this record

ConductScience Library. Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis. Papers, record 32192585. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32192585

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Drug-associated adverse events in the treatment of multidrug-resistant tuberculosis: an individual patient data meta-analysis.
PubMed
Journal
Lancet Respir Med
PubMed
Year
2020
PubMed
Publication types
Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Systematic Review, Network Meta-Analysis
PubMed
Citations, by iCite
203
iCite
Relative citation ratio, by iCite
12.7
iCite
Revised in PubMed
2026-05-18
PubMed

Authors23

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Lan ZZhiyi
2Ahmad NNafees
3Baghaei PParvaneh
4Barkane LLinda
5Benedetti AAndrea
6Brode SKSarah K
7Brust JCMJames C M
8Campbell JRJonathon R
9Chang VWLVicky Wai Lai
10Falzon DDennis
11Guglielmetti LLorenzo
12Isaakidis PPetros
13Kempker RRRussell R
14Kipiani MMaia
15Kuksa LLiga
16Lange CChristoph
17Laniado-Laborín RRafael
18Nahid PPayam
19Rodrigues DDenise
20Singla RRupak

Source PubMed

See all 23 authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antitubercular AgentsMajor topic
Drug-Related Side Effects and Adverse ReactionsMajor topic
Tuberculosis, Multidrug-ResistantMajor topic
Tuberculosis, PulmonaryMajor topic
Adult
Aminosalicylic Acid
Canada
Clofazimine
Diarylquinolines
Female
Fluoroquinolones
Humans
Incidence
Linezolid
Male
Mycobacterium tuberculosis

Source PubMed

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
001World Health OrganizationInternationalPubMedPubMed
D43 TW007124FIC NIH HHSUnited StatesD43TW007124PubMed and NIHNIH RePORTER

References64

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
129,122,917Final treatment outcomes of multidrug- and extensively drug-resistant tuberculosis patients in Latvia receiving delamanid-containing regimens.Eur Respir J2017https://conductscience.org/library/papers/29122917PubMed
228,656,130Tuberculosis control, and the where and why of artificial intelligence.ERJ Open Res2017https://conductscience.org/library/papers/28656130PubMed
329,037,291The devil we know: is the use of injectable agents for the treatment of MDR-TB justified?Int J Tuberc Lung Dis2017https://conductscience.org/library/papers/29037291PubMed
417,988,949Meta-analysis for ranked discovery datasets: theoretical framework and empirical demonstration for microarrays.Comput Biol Chem2008https://conductscience.org/library/papers/17988949PubMed
519,494,215The diarylquinoline TMC207 for multidrug-resistant tuberculosis.N Engl J Med2009https://conductscience.org/library/papers/19494215PubMed
626,965,290Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB.Eur Respir J2016https://conductscience.org/library/papers/26965290PubMed
720,185,428Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004.Eur Respir J2010https://conductscience.org/library/papers/20185428PubMed
823,735,593Safety of cycloserine and terizidone for the treatment of drug-resistant tuberculosis: a meta-analysis.Int J Tuberc Lung Dis2013https://conductscience.org/library/papers/23735593PubMed
920,356,997Assessment of linezolid efficacy and safety in MDR- and XDR-TB: an Indian perspective.Eur Respir J2010https://conductscience.org/library/papers/20356997PubMed
1018,083,461The binomial distribution of meta-analysis was preferred to model within-study variability.J Clin Epidemiol2008https://conductscience.org/library/papers/18083461PubMed
1126,985,890Carbapenems to Treat Multidrug and Extensively Drug-Resistant Tuberculosis: A Systematic Review.Int J Mol Sci2016https://conductscience.org/library/papers/26985890PubMed
1228,419,314Adverse drug reactions during drug-resistant TB treatment in high HIV prevalence settings: a systematic review and meta-analysis.J Antimicrob Chemother2017https://conductscience.org/library/papers/28419314PubMed
1323,018,916Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis.Eur Respir J2013https://conductscience.org/library/papers/23018916PubMed
1420,132,617Adverse events related to multidrug-resistant tuberculosis treatment, Latvia, 2000-2004.Int J Tuberc Lung Dis2010https://conductscience.org/library/papers/20132617PubMed
1524,384,902Safety and availability of clofazimine in the treatment of multidrug and extensively drug-resistant tuberculosis: analysis of published guidance and meta-analysis of cohort studies.BMJ Open2014https://conductscience.org/library/papers/24384902PubMed
1618,976,552Multidrug- and extensively drug-resistant tuberculosis, Germany.Emerg Infect Dis2008https://conductscience.org/library/papers/18976552PubMed
1715,971,391Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis.Int J Tuberc Lung Dis2005https://conductscience.org/library/papers/15971391PubMed
1827,334,498Efficacy and safety profile of linezolid in the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis: a systematic review and meta-analysis.Ann Clin Microbiol Antimicrob2016https://conductscience.org/library/papers/27334498PubMed
1928,529,205Effectiveness and safety of bedaquiline-containing regimens in the treatment of MDR- and XDR-TB: a multicentre study.Eur Respir J2017https://conductscience.org/library/papers/28529205PubMed
2028,331,044Effectiveness and safety of clofazimine in multidrug-resistant tuberculosis: a nationwide report from Brazil.Eur Respir J2017https://conductscience.org/library/papers/28331044PubMed

See all 64 references

Cited by143

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 203 citations.

PMIDTitleJournalYearIn PapersSource
42,890,781Treatment outcomes and post-treatment mortality among people with multidrug/rifampicin-resistant tuberculosis in Sierra Leone: a national cohort study.Lancet Reg Health Afr2026https://conductscience.org/library/papers/42890781PubMed
42,757,111Challenges in causality assessment of renal dysfunction during sequential treatment for presumed rifampicin-resistant tuberculosis in an elderly patient.IDCases2026https://conductscience.org/library/papers/42757111PubMed
42,746,380Real-world treatment outcomes and adverse events during BPaLM therapy for rifampicin-resistant TB.IJTLD Open2026https://conductscience.org/library/papers/42746380PubMed
42,638,850Evaluation of a short, all oral treatment regimen including bedaquiline, delamanid, linezolid, clofazimine, and pyrazinamide named "Regimen C" for pre-XDR tuberculosis in Niger.Front Tuberc2025https://conductscience.org/library/papers/42638850PubMed
42,517,152Characteristics, Treatment Strategies, and Long-term Health Outcomes of People With Bedaquiline-resistant Tuberculosis in Karakalpakstan, Uzbekistan-A Retrospective Cohort Study.Open Forum Infect Dis2026https://conductscience.org/library/papers/42517152PubMed
42,121,320Adverse events in bedaquiline- and pretomanid-based regimens for drug-resistant tuberculosis from trial, implementation and pharmacovigilance studies.Br J Clin Pharmacol2026https://conductscience.org/library/papers/42121320PubMed
42,094,621Molecular Mechanisms of Resistance and Treatment Efficacy of Delamanid Against Mycobacterium tuberculosis: A Systematic Review.Health Sci Rep2026https://conductscience.org/library/papers/42094621PubMed
42,036,916Factors Associated With Tuberculosis Treatment Failure Among Hill Tribe and Stateless People in Chiang Rai Province, Thailand: A Case-Control Study.Trop Med Int Health2026https://conductscience.org/library/papers/42036916PubMed
42,012,189The Mycobacterium tuberculosis Rv0132c Gene Product Mtb-FGD2 Can Act as an F420-Dependent Glucose Dehydrogenase.Proteins2026https://conductscience.org/library/papers/42012189PubMed
42,010,496Towards precision dosing of contezolid: moderate hepatic impairment increases plasma concentration of contezolid in anti-tuberculosis treatment.BMC Infect Dis2026https://conductscience.org/library/papers/42010496PubMed
41,994,187Safety of treatment regimens for drug-resistant TB over a 15-year period: a scoping review.IJTLD Open2026https://conductscience.org/library/papers/41994187PubMed
41,957,325Contezolid in tuberculosis therapy: a retrospective analysis of real-world practice in China.Eur J Clin Microbiol Infect Dis2026https://conductscience.org/library/papers/41957325PubMed
41,888,729Cohort evaluation of an all-oral shorter regimen for drug-resistant tuberculosis in Ecuador.BMC Infect Dis2026https://conductscience.org/library/papers/41888729PubMed
41,877,621Adverse drug reactions among children with tuberculosis in China: a multicentre study, 2017-2022.Ann Med2026https://conductscience.org/library/papers/41877621PubMed
41,735,928Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China.BMC Infect Dis2026https://conductscience.org/library/papers/41735928PubMed
41,709,251Pattern and predictors of drug resistance and treatment outcome in tuberculosis patients at the centers of programmatic management of drug-resistant tuberculosis in Lahore, Pakistan.BMC Public Health2026https://conductscience.org/library/papers/41709251PubMed
41,559,620Success rates of DR-TB patients and associated factors in Tanzania: a six-year cohort study.BMC Infect Dis2026https://conductscience.org/library/papers/41559620PubMed
41,519,798Preparation and in vitro sustained release performance of thermosensitive gel microsphere composite loaded with Anti-Tuberculosis drug PaMZ/BMP-2.J Orthop Surg Res2026https://conductscience.org/library/papers/41519798PubMed
41,329,266The Structure, Properties, and Clinical Utility of Contezolid for Antituberculosis: A Narrative Review.Infect Dis Ther2026https://conductscience.org/library/papers/41329266PubMed
41,322,740Assessment of Medication Adherence to Anti-tuberculosis Treatment Among Patients With Tuberculosis at a Tertiary Care Hospital in South Gujarat, India.Cureus2025https://conductscience.org/library/papers/41322740PubMed

See all 143 cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920

Source NCBI Gene

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32192585

GET https://conductscience.org/api/papers/v1/32192585/authors?page=2